Remeglurant

Remeglurant
Clinical data
Other namesMRZ-8456
ATC code
  • None
Identifiers
IUPAC name
  • (6-Bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC17H15BrN4O
Molar mass371.238 g·mol−1
3D model (JSmol)
SMILES
  • C[C@@H]1c2ccccc2CCN1C(=O)c3cc4ncc(cn4n3)Br
InChI
  • InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1
  • Key:TUYZYSNXXSTKQX-LLVKDONJSA-N

Remeglurant (INN; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor.[1][2][3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.[3]

See also

References

  1. ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. World Health Organization. 27 (2).
  2. ↑ US 7985753, Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V, "Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators.", issued 4 August 2006, assigned to Merz Pharmaceuticals GmbH
  3. 1 2 "Remeglurant". Adis Insight. Springer Nature Switzerland AG.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.